December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

16.47 -0.33 (-1.98%)
Streaming Delayed Price Updated: 2:16 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
News headline image
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.